new
   Use of Reblozyl in specific populations
500
Jul 25, 2025

This article introduces the use of Reblozyl in specific populations to help patients avoid risks.

Use of Reblozyl in specific populations

Pregnancy

According to the results of animal studies, pregnant women using Reblozyl may cause harm to the fetus.

Lactation

Animal studies have shown that breast-fed children may experience serious adverse reactions, so it is recommended that lactating patients not breastfeed during treatment with Reblozyl and within 3 months after the last dose.

Women and men with fertility plans

It is recommended that women with fertility plans take a pregnancy test before receiving Reblozyl treatment.

Pregnant women may suffer embryo-fetal damage during treatment with Reblozyl, and female patients with fertility plans are advised to take effective contraceptive measures during treatment and for at least 3 months after the last dose.

According to the results of animal studies, Reblozyl may impair the fertility of female animals. The adverse effects on the fertility of female organisms are reversible after a 14-week recovery period.

Use in pediatric patients

The safety and efficacy of Reblozyl in pediatric patients have not been established. Based on animal studies, Reblozyl is not recommended for use in pediatric patients.

Use in Elderly Patients

Clinical trials for use in elderly patients with beta-thalassemia did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients.

In clinical studies of Reblozyl for the treatment of MDS-RS and MDS/MPN-RS-T anemia, 206 (79%) patients were ≥ 65 years of age and 93 (36%) patients were ≥ 75 years of age. There were no differences in safety or effectiveness between elderly and younger patients.

Precautions

Before receiving Reblozyl, tell your doctor if you have or have had blood clots; Have or have had high blood pressure (hypertension); Take hormone replacement therapy or birth control pills (oral contraceptives); Have had your spleen removed (splenectomy); Do you smoke;Are you pregnant or planning to become pregnant.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
RELATED ARTICLES
Reblozyl instructions

Luspatercept (REBLOZYL), developed by Bristol-Myers Squibb, has been approved for marketing in many countries for...

Friday, July 25th, 2025, 17:16
Clinical trial efficacy of Reblozyl

Reblozyl is a recombinant fusion protein that binds to multiple endogenous TGF-β superfamily ligands, thereby...

Friday, July 25th, 2025, 17:08
Adverse reactions reported in Reblozyl clinical trials

The most common adverse reactions (>10%) during the use of Reblozyl were fatigue, headache, musculoskeletal...

Friday, July 25th, 2025, 16:54
Use of Reblozyl in specific populations

This article introduces the use of Reblozyl in specific populations to help patients avoid risks.

Use of...

Friday, July 25th, 2025, 16:27
RELATED MEDICATIONS
Contact Medical Consultant
Global Drug Search
Clinical recruitment
overseas medical treatment
Remote consultation
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Click to submit medical consultant
Contact Us
Mailbox:Info@Lucius.La
Welcome To Consult
Ucius Pharmaceuticals (Lao) Co.,Ltd All Rights Reserved